{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:35Z","timestamp":1788454835367,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.02.050","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T11:07:21Z","timestamp":1647515241000},"page":"A122-A127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"S1","title":["Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience"],"prefix":"10.1016","volume":"41","author":[{"given":"Grace R.","family":"Macklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Peak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eisenhawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyrouz","family":"Kurji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Konz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novilia Sjafri","family":"Bachtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda S.","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zipursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.050_b0005","series-title":"Plotkin's Vaccines","first-page":"866","article-title":"Poliovirus vaccine\u2013live","author":"Sutter","year":"2018"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.050_b0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"issue":"6489","key":"10.1016\/j.vaccine.2022.02.050_b0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.050_b0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis","volume":"19","author":"Macklin","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.050_b0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/QCO.0000000000000667","article-title":"Final frontiers of the polio eradication endgame","volume":"33","author":"Bandyopadhyay","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.050_b0030","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.050_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Konopka-Anstadt","year":"2020","journal-title":"npj Vaccines"},{"issue":"10193","key":"10.1016\/j.vaccine.2022.02.050_b0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.vaccine.2022.02.050_b0045","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/fmb-2019-0196","article-title":"Poliopolis: pushing boundaries of scientific innovations for disease eradication","volume":"14","author":"Van Damme","year":"2019","journal-title":"Future microbiology"},{"key":"10.1016\/j.vaccine.2022.02.050_b0050","article-title":"Intestinal antibody responses to two novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium","author":"Brickley","year":"2020","journal-title":"J Infect Dis"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.02.050_b0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials","volume":"397","author":"De Coster","year":"2021","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.02.050_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.02.050_b0065","unstructured":"World Health Organisation. Emergency Use Listing Procedure, Version 9. Geneva, Switzerland: World Health Organisation; 2020. Available from: https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/documents\/EUL_Procedure_Jan2020.pdf."},{"issue":"10163","key":"10.1016\/j.vaccine.2022.02.050_b0070","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/S0140-6736(18)33115-5","article-title":"WHO keeps polio on the international health emergency list","volume":"392","author":"Zarocostas","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.02.050_b0075","unstructured":"World Health Organisation. Roadmap for assessment of nOPV2 manufactured by PT Biofarma under the EUL procedure World Health Organisation; 2020. Available from: https:\/\/www.who.int\/medicines\/news\/2020\/roadmap-assessment-nOPV2.pdf?ua=1."},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.050_b0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1128\/JVI.01532-15","article-title":"Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria","volume":"90","author":"Famulare","year":"2016","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.050_b0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S1473-3099(17)30358-4","article-title":"Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study","volume":"17","author":"Taniuchi","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.050_b0090","doi-asserted-by":"crossref","first-page":"e0208336","DOI":"10.1371\/journal.pone.0208336","article-title":"Assessing the sensitivity of the polio environmental surveillance system","volume":"13","author":"Kroiss","year":"2018","journal-title":"PLoS One"},{"issue":"48","key":"10.1016\/j.vaccine.2022.02.050_b0095","first-page":"585","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2020\u2013conclusions and recommendations","volume":"95","author":"Organization","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2022.02.050_b0100","unstructured":"Organization WH. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2021\u2013conclusions and recommendations. Weekly Epidemiological Record [No 50] 2021;96:613\u201332."},{"key":"10.1016\/j.vaccine.2022.02.050_b0105","unstructured":"World Health Organisation. Executive Board, 146th session, Agenda item 16.1 - Polio Eradication World Health Organisation: World Health Organisation; 2020. Available from: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB146\/B146(11)-en.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:59Z","timestamp":1759404299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":21,"alternative-id":["S0264410X22001955"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}